Real-world evidence on Obstructive Sleep Apnea in Type 2 Diabetes and Impact of Continuous Positive Airway Pressure Therapy on Glycemic Control and Other Complications
Author(s): Pravin Gulab Dandekar*, Pranay Anil Jain, Shefali Jain and Vaishali Bhalavi
Abstract
Introduction: Obstructive Sleep Apnea (OSA) is a chronic respiratory disorder and is recurrent comorbidity in people with type 2 diabetes (T2D) with high prevalence and morbidity. Evidence suggests that the majority of patients with T2D also have OSA. The relationship between OSA and T2D may be bidirectional in nature and untreated OSA in these patients results in poor glycemic control and complications. Aims: To assess the prevalence and severity of OSA in people with T2D and the impact of continuous positive airway pressure (CPAP) therapy on glycemic control, and other complications. Materials and Methods: People with T2D suspected of OSA and who underwent polysomnography (PSG) from the department of medicine, Chirayu medical college and hospital, Bhopal were recruited for this study, from September 2021 to April 2022. Thirty people with T2D were included in the study. The participants were followed up for 12 weeks and 24 weeks respectively. Results: The mean age of the participants was 50.73± 3.60. The majority of the participants 66.7 % were male. 50% of the participants were overweight and 33% were obese. The mean fasting blood glucose at 12 weeks was 154.47 mg/dl and at 24 weeks 112.93 mg/dl, the mean postprandial (PP) blood glucose was 254.47 mg/dl at 12 weeks, and 212.93mg/dl at 24 weeks. The mean HbA1c was 8.9% at 12 weeks and at 24 weeks it was 8.3% (p=0.0301) a statistically significant drop in mean HbA1c was noted. Conclusion: Treatment of OSA with CPAP reduces HbA1c in a significant number of patients and this also had a positive impact on blood pressure parameters.